(Q35209364)

7 August 2017

1 reference

title

Tracking death dealing by Fas and TRAIL in lymphatic neoplastic disorders: pathways, targets, and therapeutic tools (English)

1 reference

7 August 2017

Richard Greil

1

1 reference

7 August 2017

Gabriele Anether

series ordinal

2

1 reference

7 August 2017

Karin Johrer

series ordinal

3

1 reference

7 August 2017

Inge Tinhofer

series ordinal

4

1 reference

7 August 2017

1 September 2003

1 reference

Journal of Leukocyte Biology

7 August 2017

1 reference

7 August 2017

74

1 reference

7 August 2017

3

1 reference

7 August 2017

311-330

1 reference

Lpr and gld: single gene models of systemic autoimmunity and lymphoproliferative disease

7 August 2017

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0802416

Apoptosis in sepsis: a new target for therapeutic exploration

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0802416

Structure and function of Fas/Fas ligand

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0802416

The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0802416

Two CD95 (APO-1/Fas) signaling pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0802416

Generalized lymphoproliferative disease in mice, caused by a point mutation in the Fas ligand

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0802416

Human autoimmune lymphoproliferative syndrome, a defect in the apoptosis-inducing Fas receptor: a lesson from the mouse model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0802416

Characterization of the in vivo function of TNF-alpha-related apoptosis-inducing ligand, TRAIL/Apo2L, using TRAIL/Apo2L gene-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0802416

FADD: essential for embryo development and signaling from some, but not all, inducers of apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0802416

Fas-mediated apoptosis and activation-induced T-cell proliferation are defective in mice lacking FADD/Mort1

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0802416

T cell-specific FADD-deficient mice: FADD is required for early T cell development

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0802416

Reduced apoptosis and cytochrome c-mediated caspase activation in mice lacking caspase 9

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0802416

Decreased apoptosis in the brain and premature lethality in CPP32-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0802416

Generation and characterization of Smac/DIABLO-deficient mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0802416

Characterization of XIAP-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0802416

Targeted disruption of Bcl-2 alpha beta in mice: occurrence of gray hair, polycystic kidney disease, and lymphocytopenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0802416

Activation of Fas by FasL induces apoptosis by a mechanism that cannot be blocked by Bcl-2 or Bcl-x(L)

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0802416

IAP family proteins--suppressors of apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0802416

Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0802416

Molecular determinants of the caspase-promoting activity of Smac/DIABLO and its role in the death receptor pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0802416

Activation of caspase-8 in drug-induced apoptosis of B-lymphoid cells is independent of CD95/Fas receptor-ligand interaction and occurs downstream of caspase-3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0802416

Caspase-9 processing by caspase-3 via a feedback amplification loop in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0802416

Maximal proliferation of cytotoxic T lymphocytes requires reverse signaling through Fas ligand

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0802416

Identification and characterization of a new member of the TNF family that induces apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0802416

Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0802416

Safety and antitumor activity of recombinant soluble Apo2 ligand

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0802416

The receptor for the cytotoxic ligand TRAIL

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0802416

Apo2L/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5.

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0802416

FADD is required for DR4- and DR5-mediated apoptosis: lack of trail-induced apoptosis in FADD-deficient mouse embryonic fibroblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0802416

Inherited human Caspase 10 mutations underlie defective lymphocyte and dendritic cell apoptosis in autoimmune lymphoproliferative syndrome type II

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0802416

TRAIL receptor-2 signals apoptosis through FADD and caspase-8

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0802416

The novel receptor TRAIL-R4 induces NF-kappaB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0802416

Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0802416

In vitro susceptibility to TRAIL-induced apoptosis of acute leukemia cells in the context of TRAIL receptor gene expression and constitutive NF-kappa B activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0802416

Transfection of caspase-3 in the caspase-3-deficient Hodgkin's disease cell line, KMH2, results in enhanced sensitivity to CD95-, TRAIL-, and ARA-C-induced apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0802416

Induction of a TRAIL-mediated suicide program by interferon alpha in primary effusion lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0802416

Involvement of TRAIL/TRAIL-R interaction in IFN-alpha-induced apoptosis of Daudi B lymphoma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0802416

Apo2L/TRAIL and Bcl-2-related proteins regulate type I interferon-induced apoptosis in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0802416

TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0802416

CD95's deadly mission in the immune system

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0802416

A membrane-bound Fas decoy receptor expressed by human thymocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0802416

A role for Fas in negative selection of thymocytes in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0802416

Cell-autonomous Fas (CD95)/Fas-ligand interaction mediates activation-induced apoptosis in T-cell hybridomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0802416

The dual functions of fas ligand in the regulation of peripheral CD8+ and CD4+ T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0802416

Fas ligand mediates activation-induced cell death in human T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0802416

Surface expression of TRAIL/Apo-2 ligand in activated mouse T and B cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0802416

Tumor necrosis factor-related apoptosis-inducing ligand in T cell development: sensitivity of human thymocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0802416

FLICE-inhibitory protein is a key regulator of germinal center B cell apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0802416

Death-receptor contribution to the germinal-center reaction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0802416

Fas is required for clonal selection in germinal centers and the subsequent establishment of the memory B cell repertoire.

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0802416

Fas-L up-regulation by highly malignant myeloma plasma cells: role in the pathogenesis of anemia and disease progression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0802416

Fas ligand expression in Hodgkin lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0802416

CD95 ligand (CD95L) in normal human lymphoid tissues: a subset of plasma cells are prominent producers of CD95L.

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0802416

Negative regulation of erythroblast maturation by Fas-L(+)/TRAIL(+) highly malignant plasma cells: a major pathogenetic mechanism of anemia in multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0802416

TRAIL (Apo2L) suppresses growth of primary human leukemia and myelodysplasia progenitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0802416

Mice defective in two apoptosis pathways in the myeloid lineage develop acute myeloblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0802416

Human dendritic cells mediate cellular apoptosis via tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0802416

Critical contribution of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) to apoptosis of human CD4+ T cells in HIV-1-infected hu-PBL-NOD-SCID mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0802416

Measles virus induces functional TRAIL production by human dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0802416

Spontaneous development of plasmacytoid tumors in mice with defective Fas-Fas ligand interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0802416

The inhibitor of death receptor signaling, FLICE-inhibitory protein defines a new class of tumor progression factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0802416

A tumor-suppressor function for Fas (CD95) revealed in T cell-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0802416

An inherited disorder of lymphocyte apoptosis: the autoimmune lymphoproliferative syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0802416

Defective CD95/APO-1/Fas signal complex formation in the human autoimmune lymphoproliferative syndrome, type Ia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0802416

Pathological findings in human autoimmune lymphoproliferative syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0802416

Fas gene mutations in the Canale-Smith syndrome, an inherited lymphoproliferative disorder associated with autoimmunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0802416

The development of lymphomas in families with autoimmune lymphoproliferative syndrome with germline Fas mutations and defective lymphocyte apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0802416

The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0802416

Not so Fas: Re-evaluating the mechanisms of immune privilege and tumor escape

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0802416

Fas ligand expression in islets of Langerhans does not confer immune privilege and instead targets them for rapid destruction

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0802416

Gene transfer of Fas ligand induces tumor regression in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0802416

Increased susceptibility to tumor initiation and metastasis in TNF-related apoptosis-inducing ligand-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0802416

Critical role for tumor necrosis factor-related apoptosis-inducing ligand in immune surveillance against tumor development

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0802416

Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) contributes to interferon gamma-dependent natural killer cell protection from tumor metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0802416

The involvement of TNF-alpha-related apoptosis-inducing ligand in the enhanced cytotoxicity of IFN-beta-stimulated human dendritic cells to tumor cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0802416

Mutation analysis of the FAS and TNFR apoptotic cascade genes in hematological malignancies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0802416

Mutation analysis of CD95 (APO-1/Fas) in childhood B-lineage acute lymphoblastic leukaemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0802416

Loss of Fas (CD95/APO-1) regulatory function is an important step in early MALT-type lymphoma development.

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0802416

Fas/Apo-1 (CD95)-mediated and CD95-independent apoptosis of malignant plasma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0802416

Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0802416

Frequent nuclear localization of ICAD and cytoplasmic co-expression of caspase-8 and caspase-3 in human lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0802416

Lethal effect of the anti-Fas antibody in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0802416

Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0802416

Clonal variability in CD95 expression is the major determinant in Fas-medicated, but not chemotherapy-medicated apoptosis in the RPMI 8226 multiple myeloma cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0802416

fas-mediated lysis of chronic lymphocytic leukaemia cells: role of type I versus type II cytokines and autologous fasL-expressing T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0802416

Interleukin-15 as a potential costimulatory cytokine in CD154 gene therapy of chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0802416

Cellular origin of human B-cell lymphomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0802416

Bryostatin and CD40-ligand enhance apoptosis resistance and induce expression of cell survival genes in B-cell chronic lymphocytic leukaemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0802416

What is the real role of CD40 in cancer immunotherapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0802416

A novel murine anti-human Fas mAb which mitigates lymphadenopathy without hepatotoxicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0802416

Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0802416

Combined effect of tumor necrosis factor-related apoptosis-inducing ligand and ionizing radiation in breast cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0802416

Retinoic acid-induced apoptosis in leukemia cells is mediated by paracrine action of tumor-selective death ligand TRAIL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0802416

Regulation of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in thyroid carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0802416

TRAIL enhances thymidine kinase/ganciclovir gene therapy of neuroblastoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0802416

Ectopic overexpression of second mitochondria-derived activator of caspases (Smac/DIABLO) or cotreatment with N-terminus of Smac/DIABLO peptide potentiates epothilone B derivative-(BMS 247550) and Apo-2L/TRAIL-induced apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0802416

Smac agonists sensitize for Apo2L/TRAIL- or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0802416

Synthetic Smac/DIABLO peptides enhance the effects of chemotherapeutic agents by binding XIAP and cIAP1 in situ

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0802416

The triterpenoid CDDO induces apoptosis in refractory CLL B cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0802416

Acute rejection of murine bone marrow allografts by natural killer cells and T cells. Differences in kinetics and target antigens recognized

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0802416

Graft-versus-host-disease-associated lymphoid hypoplasia and B cell dysfunction is dependent upon donor T cell-mediated Fas-ligand function, but not perforin function

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0802416

The role of cell-mediated cytotoxicity in acute GVHD after MHC-matched allogeneic bone marrow transplantation in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0802416

Perforin/granzyme-dependent and independent mechanisms are both important for the development of graft-versus-host disease after murine bone marrow transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0802416

Decreased tumor surveillance in perforin-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0802416

A Fas-based suicide switch in human T cells for the treatment of graft-versus-host disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0802416

Cytotoxic T cells deficient in both functional fas ligand and perforin show residual cytolytic activity yet lose their capacity to induce lethal acute graft-versus-host disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0802416

T cells require TRAIL for optimal graft-versus-tumor activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0802416

Control of apoptosis and mitotic spindle checkpoint by survivin

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0802416

Direct in vivo transfection of antisense Fas-ligand reduces tumor growth and invasion

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0802416

Chronic restraint stress promotes lymphocyte apoptosis by modulating CD95 expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0802416

Human brain-cell death induced by tumour-necrosis-factor-related apoptosis-inducing ligand (TRAIL)

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0802416

Survivin is expressed on CD40 stimulation and interfaces proliferation and apoptosis in B-cell chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0802416

Role of the CD40 and CD95 (APO-1/Fas) antigens in the apoptosis of human B-cell malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0802416

Ionizing radiation sensitizes erythroleukemic cells but not normal erythroblasts to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated cytotoxicity by selective up-regulation of TRAIL-R1

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0802416

21 January 2018

Identifiers

DOI

10.1189/JLB.0802416

1 reference

7 August 2017

1 reference